866-997-4948(US-Canada Toll Free)

Drug Eluting Stents (DES)-Medical Devices Pipeline Assessment, 2019

Published By :

GlobalData

Published Date : Dec 2019

Category :

Medical Equipments

No. of Pages : 247 Pages

Drug Eluting Stents (DES) - Medical Devices Pipeline Assessment, 2019

Summary

GlobalData's Medical Devices sector report, Drug Eluting Stents (DES) - Medical Devices Pipeline Assessment, 2019" provides an overview of Drug Eluting Stents (DES) currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Drug Eluting Stents (DES) pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

- Extensive coverage of the Drug Eluting Stents (DES) under development
- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
- The report reviews the major players involved in the development of Drug Eluting Stents (DES) and list all their pipeline projects
- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
- The report provides key clinical trial data of ongoing trials specific to pipeline products
- Recent developments in the segment / industry

Reasons to buy

The report enables you to -
- Formulate significant competitor information, analysis, and insights to improve R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of Drug Eluting Stents (DES) under development
- Develop market-entry and market expansion strategies
- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
- In-depth analysis of the products current stage of development, territory and estimated launch date
Table of Contents
1.1 List of Tables 6
1.2 List of Figures 14
2 Introduction 15
2.1 Drug Eluting Stents (DES) Overview 15
3 Products under Development 16
3.1 Drug Eluting Stents (DES) - Pipeline Products by Stage of Development 16
3.2 Drug Eluting Stents (DES) - Pipeline Products by Territory 17
3.3 Drug Eluting Stents (DES) - Pipeline Products by Regulatory Path 18
3.4 Drug Eluting Stents (DES) - Pipeline Products by Estimated Approval Date 19
3.5 Drug Eluting Stents (DES) - Ongoing Clinical Trials 20
4 Drug Eluting Stents (DES) - Pipeline Products under Development by Companies 21
4.1 Drug Eluting Stents (DES) Companies - Pipeline Products by Stage of Development 21
4.2 Drug Eluting Stents (DES) - Pipeline Products by Stage of Development 23
5 Drug Eluting Stents (DES) Companies and Product Overview 25
5.1 Aachen Resonance GmbH Company Overview 25
5.1.1 Aachen Resonance GmbH Pipeline Products & Ongoing Clinical Trials Overview 25
5.2 Abbott Vascular Inc Company Overview 26
5.2.1 Abbott Vascular Inc Pipeline Products & Ongoing Clinical Trials Overview 26
5.3 Adcomp Technologies Inc. Company Overview 34
5.3.1 Adcomp Technologies Inc. Pipeline Products & Ongoing Clinical Trials Overview 34
5.4 Advanced Bifurcation Systems Inc Company Overview 35
5.4.1 Advanced Bifurcation Systems Inc Pipeline Products & Ongoing Clinical Trials Overview 35
5.5 Aeon Bioscience Company Overview 36
5.5.1 Aeon Bioscience Pipeline Products & Ongoing Clinical Trials Overview 36
5.6 AlviMedica Medical Technologies Inc Company Overview 37
5.6.1 AlviMedica Medical Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 37
5.7 B. Braun Melsungen AG Company Overview 45
5.7.1 B. Braun Melsungen AG Pipeline Products & Ongoing Clinical Trials Overview 45
5.8 Biosensors International Group Ltd Company Overview 46
5.8.1 Biosensors International Group Ltd Pipeline Products & Ongoing Clinical Trials Overview 46
5.9 Biotronik AG Company Overview 52
5.9.1 Biotronik AG Pipeline Products & Ongoing Clinical Trials Overview 52
5.10 Biotronik SE & Co KG Company Overview 69
5.10.1 Biotronik SE & Co KG Pipeline Products & Ongoing Clinical Trials Overview 69
5.11 Boston Scientific Corp Company Overview 70
5.11.1 Boston Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview 70
5.12 Cardionovum GmbH Company Overview 76
5.12.1 Cardionovum GmbH Pipeline Products & Ongoing Clinical Trials Overview 76
5.13 Cardiorev Pte Ltd (Inactive) Company Overview 79
5.13.1 Cardiorev Pte Ltd (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 79
5.14 Columbia University Company Overview 80
5.14.1 Columbia University Pipeline Products & Ongoing Clinical Trials Overview 80
5.15 Concept Medical Inc Company Overview 81
5.15.1 Concept Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 81
5.16 Cordis Corp Company Overview 85
5.16.1 Cordis Corp Pipeline Products & Ongoing Clinical Trials Overview 85
5.17 DISA Vascular (Pty) Ltd Company Overview 88
5.17.1 DISA Vascular (Pty) Ltd Pipeline Products & Ongoing Clinical Trials Overview 88
5.18 Elixir Medical Corp Company Overview 89
5.18.1 Elixir Medical Corp Pipeline Products & Ongoing Clinical Trials Overview 89
5.19 Envision Scientific Pvt Ltd Company Overview 91
5.19.1 Envision Scientific Pvt Ltd Pipeline Products & Ongoing Clinical Trials Overview 91
5.20 I.B.S. S.p.A. Company Overview 93
5.20.1 I.B.S. S.p.A. Pipeline Products & Ongoing Clinical Trials Overview 93
6 Drug Eluting Stents (DES)- Recent Developments 161
6.1 Nov 19, 2019: Medtronic reports second quarter financial results for the year 2019 161
6.2 Nov 14, 2019: Medtronic highlights leadership in inclusion, diversity, and equity in 2019 integrated performance report 163
6.3 Nov 13, 2019: Abbott announces Robert B. Ford to Succeed Miles D. White as Chief Executive Officer on March 31, 2020 164
6.4 Oct 30, 2019: Orsiro Coronary Drug-Eluting Stent receives market approval in China 165
6.5 Oct 23, 2019: Boston Scientific announces results for third quarter 2019 165
7 Appendix 244
7.1 Methodology 244
7.2 About GlobalData 247
7.3 Contact Us 247
7.4 Disclaimer 247

List of Tables
Table 1: Drug Eluting Stents (DES) - Pipeline Products by Stage of Development
Table 2: Drug Eluting Stents (DES) - Pipeline Products by Territory
Table 3: Drug Eluting Stents (DES) - Pipeline Products by Regulatory Path
Table 4: Drug Eluting Stents (DES) - Pipeline Products by Estimated Approval Date
Table 5: Drug Eluting Stents (DES) - Ongoing Clinical Trials
Table 6: Drug Eluting Stents (DES) Companies - Pipeline Products by Stage of Development
Table 7: Drug Eluting Stents (DES) - Pipeline Products by Stage of Development
Table 8: Aachen Resonance GmbH Pipeline Products & Ongoing Clinical Trials Overview
Table 9: ARtax Coronary Stent - Product Status
Table 10: ARtax Coronary Stent - Product Description
Table 11: Abbott Vascular Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 12: Xience SBA Everolimus Eluting Coronary Stent System - Product Status
Table 13: Xience SBA Everolimus Eluting Coronary Stent System - Product Description
Table 14: XIENCE Thin man DES - Product Status
Table 15: XIENCE Thin man DES - Product Description
Table 16: ZoMaxx Drug Eluting Coronary Stent System - Product Status
Table 17: ZoMaxx Drug Eluting Coronary Stent System - Product Description
Table 18: Abbott Vascular Inc - Ongoing Clinical Trials Overview
Table 19: Xience SBA Everolimus Eluting Coronary Stent System - A Multi-center, Randomized, Controlled Trial to Demonstrate the Safety and Effectiveness of the MiStent II for the Revascularization of Coronary Arteries: CRYSTAL Study
Table 20: Xience SBA Everolimus Eluting Coronary Stent System - A Prospective Global Randomized Trial Assessing the Safety and Efficacy of the BuMA Supreme Biodegradable Drug Coated Coronary Stent System for Coronary Revascularization in Patients with Stable Coronary Artery Disease or Non-ST Segment Elevation Acute Coronary Syndromes
Table 21: Xience SBA Everolimus Eluting Coronary Stent System - A Prospective Multicenter Randomized Post Market All-comer Trial to Assess the Safety and Effectiveness of the Supraflex Sirolimus-eluting Coronary Stent System for the Treatment of Atherosclerotic Lesion(s)
Table 22: Xience SBA Everolimus Eluting Coronary Stent System - A Prospective, Open Label, Multi-center Trial of Firehawk Coronary Stent System in the Treatment of Coronary Chronic Total Artery Occlusion Lesion(S) by Optical Coherent Tomography (OCT) and Coronary Angiography
Table 23: Xience SBA Everolimus Eluting Coronary Stent System - A Safety Evaluation of 3-month Dual Antiplatelet Therapy in Subjects at High Risk of Bleeding Undergoing Percutaneous Coronary Intervention with XIENCE
Table 24: Xience SBA Everolimus Eluting Coronary Stent System - Polish Bifurcation Optimal Treatment Strategy Study for Left Main Bifurcation Percutaneous Coronary Intervention (PCI)
Table 25: Xience SBA Everolimus Eluting Coronary Stent System - Short and Optimal Duration of Dual Antiplatelet Therapy-2 Study
Table 26: XIENCE Thin man DES - A Safety Evaluation of 3-month Dual Antiplatelet Therapy in Subjects at High Risk of Bleeding Undergoing Percutaneous Coronary Intervention with XIENCE
Table 27: Adcomp Technologies Inc. Pipeline Products & Ongoing Clinical Trials Overview
Table 28: Dual Drug Eluting Stent - Product Status
Table 29: Dual Drug Eluting Stent - Product Description
Table 30: Advanced Bifurcation Systems Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 31: Stenting System - Drug Eluting Stent - Product Status
Table 32: Stenting System - Drug Eluting Stent - Product Description
Table 33: Aeon Bioscience Pipeline Products & Ongoing Clinical Trials Overview
Table 34: Drug Eluting Stent - Product Status
Table 35: Drug Eluting Stent - Product Description
Table 36: AlviMedica Medical Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 37: Cre8 DES - Product Status
Table 38: Cre8 DES - Product Description
Table 39: Cre8 EVO DES - Product Status
Table 40: Cre8 EVO DES - Product Description
Table 41: DES - Coracto - Product Status
Table 42: DES - Coracto - Product Description
Table 43: AlviMedica Medical Technologies Inc - Ongoing Clinical Trials Overview
Table 44: Cre8 DES - A Prospective, Multi-center, Open Label, Randomized Controlled, Two Arm Study Evaluating Safety and Efficacy of the Permanent Polymer Zotarolimus Eluting Stent Resolute Integrity Compared to the Polymer Free Amphilimus Eluting Stent Cre8
Table 45: Cre8 DES - A Prospective, Multi-center, Randomized Controlled Trial Evaluating the Safety and Efficacy of the CRE8 Sirolimus-Eluting Stent Versus the RESOLUTE Zotarolimus-eluting Stent in the Treatment of Patients with De Novo Coronary Artery Lesions
Table 46: Cre8 DES - A Prospective, Multi-center, Single-arm Observational Registry Trial Evaluating the Safety and Efficacy of CRE8 Sirolimus-Eluting Stent in the Treatment of Patients With De Novo Coronary Artery Lesions
Table 47: Cre8 DES - Prove ART (Abluminal Reservoir Technology) Clinical Benefit in Alla Comers Patients
Table 48: Cre8 DES - Safety and Performance Assessment of Coronary Drug-eluting Stent CRE8 : Post-market Observational Study
Table 49: Cre8 DES - Second-generation Drug-eluting Stents in Diabetes: A Randomized Trial: The SUGAR Trial
Table 50: Cre8 EVO DES - Randomized 2x2 Factorial Trial Comparing the Cre8 Amphilimus-sirolimus Eluting Stent versus the Synergy Everolimus-eluting Stent and a Personalized versus Standard Duration of Dual Antiplatelet Therapy in All-comers Patients Undergoing Percutaneous Coronary Intervention
Table 51: B. Braun Melsungen AG Pipeline Products & Ongoing Clinical Trials Overview
Table 52: Coroflex DEBlue - Product Status
Table 53: Coroflex DEBlue - Product Description
Table 54: Biosensors International Group Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table 55: BioFreedom Drug Coated Stent - Product Status
Table 56: BioFreedom Drug Coated Stent - Product Description
Table 57: Biosensors International Group Ltd - Ongoing Clinical Trials Overview
Table 58: BioFreedom Drug Coated Stent - A Prospective Study of the BioFreedom Biolimus A9 Drug Coated Stent in Patients at High Risk for Bleeding
Table 59: BioFreedom Drug Coated Stent - A Randomized Controlled Comparison Between One Versus More Than Six Months of Dual Antiplatelet Therapy After Biolimus A9-eluting Stent Implantation
Table 60: BioFreedom Drug Coated Stent - A Study Evaluating the Safety and Efficacy of the BioFreedom Biolimus A9 Coated Cobalt Chromium Coronary Stent System in Patients at High Risk of Bleeding
Table 61: BioFreedom Drug Coated Stent - Asian Registry of the BioFreedom BA9 Drug-Coated Coronary Stent for Patients with ST Elevation Myocardial Infarction (STEMI) Undergoing Percutaneous Coronary Intervention (PCI)
Table 62: BioFreedom Drug Coated Stent - BioFreedom PK Study in Patients with CAD Who Receive the BioFreedom Biolimus A9 Stent
Table 63: BioFreedom Drug Coated Stent - Evaluation of Effectiveness and Safety of BioFreedom Stent in Routine Clinical Practice: A Multicenter, Prospective Observational Study
Table 64: BioFreedom Drug Coated Stent - Evaluation of Effectiveness and Safety of the First, Second, and New Drug-eluting Stents in Routine Clinical Practice
Table 65: BioFreedom Drug Coated Stent - Prospective Multicenter Observational Study for Evaluating Efficacy and Safety of Biofreedom Stent in Patients with Coronary Artery Disease: Biofreedom Registry
Table 66: BioFreedom Drug Coated Stent - Randomized Comparison of a Polymer-free Biolimus-eluting BioFreedom Stent with a Biodegradable-polymer Sirolimus-eluting Orsiro Stent in Patients Treated with Percutaneous Coronary Intervention
Table 67: BioFreedom Drug Coated Stent - Randomized Comparison of Vascular Healing of a Polymer-free Biolimus-eluting BIOFREEDOM Stent with a Biodegradable-polymer Sirolimus-eluting ORSIRO Stent in Patients with ST-segment Elevation Myocardial Infarction
Table 68: BioFreedom Drug Coated Stent - Six-month Endothelial and Microvascular Function of the Bioactive Sirolimus-eluting

List of Figures
Figure 1: Drug Eluting Stents (DES) - Pipeline Products by Stage of Development
Figure 2: Drug Eluting Stents (DES) - Pipeline Products by Territory
Figure 3: Drug Eluting Stents (DES) - Pipeline Products by Regulatory Path
Figure 4: Drug Eluting Stents (DES) - Pipeline Products by Estimated Approval Date
Figure 5: Drug Eluting Stents (DES) - Ongoing Clinical Trials

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *